Showing results (1411-1420 of 3,241) with videos related to
Sort By:
Pageof 325
Journal of Clinical Pharmacy and Therapeutics|March 16, 2013
The pharmacokinetic and safety profiles of zanamivir after single and repeat intravenous administration in healthy Japanese malesY Shida, K Hara, S Nohda, et al.Journal of Clinical Pharmacy and Therapeutics|February 28, 2013
The impact of pharmacist-initiated interventions in improving acute coronary syndrome secondary prevention pharmacotherapy prescribing upon dischargeY Hassan, Y Kassab, N Abd Aziz, et al.Journal of Clinical Pharmacy and Therapeutics|February 28, 2013
Simvastatin and amlodipine induced thrombocytopenia in the same patient: double trouble and a literature reviewZorica Cvetković, Nada Suvajdžić-Vuković, Zoran Todorović, et al.Journal of Clinical Pharmacy and Therapeutics|April 19, 2013
Pharmacology of levosimendan: inotropic, vasodilatory and cardioprotective effectsA Pathak, M Lebrin, A Vaccaro, et al.Journal of Clinical Pharmacy and Therapeutics|April 1, 1990
Pharmacists' perceptions of alternative health approaches--a comparison between U.S. and British pharmacistsM V Nelson, G R Bailie, H ArenyJournal of Clinical Pharmacy and Therapeutics|July 22, 2014
Treatment of gout in a renal transplant patient leading to severe thrombocytopeniaS Weiler, N Aellig, I Fauchère, et al.Journal of Clinical Pharmacy and Therapeutics|July 26, 2014
Clinical impact of ABCC1 and ABCC2 genotypes and haplotypes in mediating imatinib resistance among chronic myeloid leukaemia patientsA Au, A A Baba, H Azlan, et al.Journal of Clinical Pharmacy and Therapeutics|August 1, 1989
Clinical pharmacokinetics of intravenous flecainide in critically ill patientsG Sangrador, A Sánchez-Alcaraz, M Rodriguez, et al.Journal of Clinical Pharmacy and Therapeutics|July 30, 2013
Neurological and psychiatric adverse events with prucalopride: case report and possible mechanismsC Carnovale, P Pellegrino, V Perrone, et al.Journal of Clinical Pharmacy and Therapeutics|November 23, 2013
Onset time of hyperkalaemia after angiotensin receptor blocker initiation: when should we start serum potassium monitoring?I-W Park, S S Sheen, D Yoon, et al.Pageof 325